SCHEMBL46342

SCHEMBL46342

COCCOc1cnc(C)cn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.37
PIK3CD O00329 1/20 0.35
PIK3CA P42336 1/20 0.35
PIK3CB P42338 1/20 0.35
PI4KA P42356 1/20 0.35
PIK3CG P48736 1/20 0.35
PI4KB Q9UBF8 1/20 0.35
BACE1 P56817 4/20 0.33
KRAS P01116 1/20 0.33
SOS1 Q07889 1/20 0.33
HPGD P15428 2/20 0.33
POLB P06746 2/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
ATM Q13315 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
PDE10A Q9Y233 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9071118 0.90 HPGD (0.34) HPGDPOLBALDH1A1CYP1A2CYP3A4
SCHEMBL7935485 0.81 GABRP (0.39) TSHRBACE1HPGDPOLBALDH1A1
SCHEMBL9071112 0.80 NCF1 (0.34) HPGDPOLBKDM4EMAPTHTT
SCHEMBL12445699 0.79 KDM4E (0.35) HPGDPOLBKDM4EMAPTHTT
SCHEMBL31445673 0.79 TAAR1 (0.34) HPGDPOLBCYP1A2CYP2C19KDM4E
SCHEMBL7935597 0.79 APP (0.35) POLBMAPT
SCHEMBL12301435 0.79 MAPT (0.44) TSHRHPGDPOLBALDH1A1CYP1A2
SCHEMBL20176279 0.79 TAAR1 (0.34) HPGDPOLBCYP1A2CYP2C19KDM4E
SCHEMBL12301544 0.79 RXRA (0.34) HPGDPOLBKDM4EMAPTHTT
SCHEMBL2669087 0.79 KMT2A (0.46) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017024180-A1 VINYL FLUORIDE CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE AMGEN INC. (US) 2017-02-09 WO disclosed
US-9452977-B2 Cyclopentylacrylamide derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2016-09-27 US disclosed
US-9452977-B2 Cyclopentylacrylamide derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2016-09-27 US disclosed
US-20150105581-A1 CYCLOPENTYLACRYLAMIDE DERIVATIVE TEIJIN LIMITED (JP) 2015-04-16 US disclosed
US-20150105581-A1 CYCLOPENTYLACRYLAMIDE DERIVATIVE TEIJIN LIMITED (JP) 2015-04-16 US disclosed
US-8946440-B2 Cyclopentylacrylamide derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2015-02-03 US disclosed
US-8946440-B2 Cyclopentylacrylamide derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2015-02-03 US disclosed
US-8173649-B2 Glucokinase activator KYORIN PHARMACEUTICAL CO., LTD. (JP) 2012-05-08 US disclosed
US-8173649-B2 Glucokinase activator KYORIN PHARMACEUTICAL CO., LTD. (JP) 2012-05-08 US disclosed
WO-2011151434-A1 NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS EUROSCREEN S.A. (BE) 2011-12-08 WO disclosed
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
US-20110160211-A1 CYCLOPENTYLACRYLAMIDE DERIVATIVE TEIJIN LIMITED (JP) 2011-06-30 US disclosed
US-20110160211-A1 CYCLOPENTYLACRYLAMIDE DERIVATIVE TEIJIN LIMITED (JP) 2011-06-30 US disclosed
EP-2275414-A1 CYCLOPENTYLACRYLIC ACID AMIDE DERIVATIVE Kyorin Pharmaceutical Co., Ltd. (JP) 2011-01-19 EP disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed
US-20100099671-A1 GLUCOKINASE ACTIVATOR TEIJIN LIMITED (JP) 2010-04-22 US disclosed
US-20100099671-A1 GLUCOKINASE ACTIVATOR TEIJIN LIMITED (JP) 2010-04-22 US disclosed
US-20100016304-A1 GLUCOKINASE ACTIVATOR TEIJIN LIMITED (JP) 2010-01-21 US disclosed
US-20100016304-A1 GLUCOKINASE ACTIVATOR TEIJIN LIMITED (JP) 2010-01-21 US disclosed
WO-2009133687-A1 CYCLOPENTYLACRYLIC ACID AMIDE DERIVATIVE 杏林製薬株式会社 (JP) 2009-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016304-A1 GLUCOKINASE ACTIVATOR GCK, GCKR, GALK1 TSHR 1676/4885PIK3CD 2490/4885PIK3CA 1667/4885
US-20110160211-A1 CYCLOPENTYLACRYLAMIDE DERIVATIVE GPR119, SLC5A1, SLC5A2 TSHR 1677/4885PIK3CD 4008/4885PIK3CA 4158/4885
US-20150105581-A1 CYCLOPENTYLACRYLAMIDE DERIVATIVE GPR119, SLC5A1, SLC5A2 TSHR 1677/4885PIK3CD 4008/4885PIK3CA 4158/4885
US-20100099671-A1 GLUCOKINASE ACTIVATOR GCK, GCKR, GALK1 TSHR 1402/4885PIK3CD 1944/4885PIK3CA 1386/4885
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 TSHR 4179/4885PIK3CD 4198/4885PIK3CA 4406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.